Safety concerns give Raptiva ‘no way back’

pharmafile | March 2, 2009 | News story | Research and Development Raptiva, drug safety 

Related Content

trump-fda

Trump’s FDA: Is the US regulator being steered by the President?

FDA activity has fallen under Donald Trump, with the number of warning letters issued by …

PV futures: Pharmacovigilance as a solution to the challenges of tomorrow

Louis Goss asks what the future might hold for the safety of pharmaceuticals and looks …

drug_safety

Drug safety: UK and EU post-Brexit

What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss …

Latest content